Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation

Cancer Research Therapy and Control

Volumn 5, Issue 4, 1998, Pages 221-228

  Zeder, Kirsten ^a   Waller, Edmund K ^a   Redei, Istvan ^a   Gerard Connaghan, D ^a   Fleming, William H ^a   Geller, Robert B ^a   Heffner, Leonard T ^a   Hillyer, Christopher D ^a   Holden, Jeannine ^a   Holland, Kent ^a   Jones, Wayne ^a   Mccollum, Joan ^a   Mogul, Mark ^a   Phillips, Carol ^a   Rodey, Glenn ^a   Wingard, John R ^a   Winton, Elliott ^a   Yeager, Andrew M ^a   Devine, Steve ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; Donor lymphocyte infusions

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKAPHERESIS; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFUSION; MALE; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD;

EID: 0031773664     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Apperley, J.F., Mauro, F.R., Goldman, J.M., Gregory, W., Arthur, C.K., Hows, J., Arcese, W., Papa, G., Mandelli, F., Wardle, D., Gravett, P., Franklin, I.M., Bandini, G., Ricci, P., Tura, S., Iacone, A., Torlontano, G., Heit, W., Champlin, R. and Gale, R.P. (1988). Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br. J. Haematol., 69, 239-45.
2. Barnes, D.W.H. and Loutit, J.F. (1957). Treatment of murine leukemia with x-rays and homologous bone marrow. Br. J. Haematol., 3, 241-52.
3. Barrett, A.J., Horowitz, M.M., Gale, R.P., Biggs, J.C., Camilla, B.M., Dicke, K.A., Gluckman, E., Good, R.A., Herzig, R.H. and Lee, M.B. (1989). Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival Blood, 74, 862-71.
4. Collins, R.H., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaule, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. and Nemunaitis, J. (1997). Donor leukocyte infusions in 140 patients with relapsed malignancy after Allogeneic Bone Marrow Transplantation. Journal of Clinical Oncology, 15, 433-44.
5. Giralt, S., Hester, J., Huh, Y., Hirsch-Ginsberg, C., Rondon, G., Seong, D., Lee, M., Gajewski, J., Van Besien, K., Khouri, I., Mehra, R., Przepiorka, D., Korbling, M., Talpaz, M., Kantarjian, H., Fischer, H., Deisseroth, A. and Champlin, R. (1995). CD 8-depleted donor lymphocyte infusion as a treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood, 86(11). 4337-4343.
6. Goldman, J.M., Gale, R.P., Horowitz, M.M., Biggs, J.C., Champlin. R.E., Gluckman, E., Hoffmann, R.G., Jacobsen, S.S., Marmont, A.M., McGlave, P.B., Messner, H.A., Rimm, A.A., Rozman, C., Speck, B., Tura, S., Weiner, R.S. and Bortin, M.M. (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase; increased risk for relapse associated with T-cell depletion. Ann Intern Med., 108, 806-14.
7. Horowitz, M.M., Gaic, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E. and Mortimmer, M.B. (1990). Graft-versus-leukemia reactions after bone marrow transplantation Blood, 75, 555-62.
8. Kaplan, E.L. and Meier, P. (1958). Nonparamatic estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-81.
9. Kolb, H. J., Mittetmuller, J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. and Wilmanns, W. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-5.
10. McGlave, P., Arthur, D., Haake, R., Hurd, D., Miller, W., Vercellotti, G,. Weisdodrf, D., Kim, T., Ramsay, N. and Kersey, J. (1987). Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J. Clin. Oncol., 5, 1033-40.
11. Mrsic, M., Horowitz, MM., Atkinson, K., Biggs, J.C., Champlin, R.E., Ehninger, G., Gajewski, J.L., Gale, R.P., Herzig, R.H., Prentice, H.G., Rozman, C., Sobocinski, K.A., Speck, B. and Bortin, M.M. (1992). Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant, 9, 269-75.
12. O'Reilly, R.I. (1983). Allogeneic bone marrow transplantation: Current status and future directions. Blood, 62, 941-64.
13. Slavin, S., Ackerstein, A., Weiss, L., Nagler, A., Or, R. and Naparstek, E. (1992). Immunotherapy of minimal residual disease by immuno-competent lymphocytes and their activation by cytokines. Cancer Invest, 10, 221-7.
14. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapeluhnik, J., Brautbar, C. and Reuven, O.R. (1996). Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87, 2195-204.
15. Soiffer, R.J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P.W., Daley, J.F. and Ritz, J. (1994). Clinical and immunological effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 84, 964-71.
16. Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., Anasetti, C., Appelbaum, F.R., Badger, C., Bensinger, B.W., Berenson, R., Bigelow, C., Cheever, M.A., Clift, R., Deeg, H.J., Doney, K., Greenberg, P., Hansen, J.A., Hill, R., Loughran, T., Martin, P., Neiman, P., Petersen, F.B., Sanders, J., Singer, J., Stewart, P. and Thomas, E.D. (1989). Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood, 73, 1720-8.
17. Thomas, E.D., Storb, R., Clift, R.A., Fefer, A., Johnson, L., Neiman, P.E., Lerner, K.G., Glucksberg, H. and Buckner, C.D. (1975). Bone Marrow Transplantation (second of two parts). N. Engl. J. Med., 292, 895-902.
18. Truitt, R.L. and Atasoylu, A.A. (1991). Impact of pre transplant conditioning and donor T cells on chimeras, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood, 77, 2515-23.
19. Truitt, R.L., LeFever, A.V., Shih, C.C.Y., Teske, J.M. and Martin, T.M., Graft-vs-leukemia effect. In: Burakoff SI, Deeg HJ, Ferrara J, Atkinson K, eds. Graft vs. host disease: immunology, pathophysiology. New York: Marcell Dekker.
20. Waller, E.K., Murray, T.W. and Boyer, M. (1996). Irradiated allogeneic lymphocytes: a novel strategy of immunotherapy. Biology of Blood and Bone Marrow Transplantation, 2, 150 (abs.).
21. Weiden, P.L., Fluomoy, N., Sanders, J., Sullivan, K.M. and Thomas, E.D. (1981). Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation, 13, 248-51.
22. Weiden, P.L., Sullivan, K.M., Fluornoy, N., Storb, R. and Thomas, E.D. (1981). Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N. Engl. Med., 304, 1529-33.
23. Weiss, L., Reich, S. and Slavin, S. (1992). Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. 1. Treatment of murine leukemia in conjunction with allogeneic bone marrow trans-plantation and IL 2-activated cell-mediated immunotherapy. Cancer Invest, 10, 19-26.
24. Weiss, L., Weigensberg, M., Morecki, S., Bar, S., Cobbold, S., Waidmann, H. and Slavin, S. (1990). Characterization of effector cells of graft vs. Leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL 1). Cancer Immunol Immunother, 31, 236-42.